Brain disorder bill hits 800 billion euros as Europe faces 'ticking bomb,' warns EBC study

5 October 2011

The annual cost of brain disorders in Europe has soared to 798 billion euros ($1,070 billion) in what a new study commissioned by the European Brain Council (EBC), describes as a social, political and financial “ticking bomb.”

The report, titled Cost of disorders of the brain in Europe 2010, argues that the bill will continue to rise as people live longer, thus representing “the number one economic challenge for European health care now and in the future.” The figure - equating to 1,550 euros per European - is more than double the estimate made in an EBC report published in 2005.

“The increasing burden and the associated increasing cost of disorders of the brain is a ticking bomb under the European economy and the EU society as a whole,” the authors say, before calling for a major increase in research funding and resources to help combat the trend.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical